Module 1: HER2-Positive Breast Cancer


Baselga J et al. A Phase III, randomized, double-blind, placebo-controlled registration trial to evaluate the efficacy and safety of placebo + trastuzumab + docetaxel vs pertuzumab + trastuzumab + docetaxel in patients with previously untreated HER2-positive metastatic breast cancer (CLEOPATRA). *Proc SABCS* 2011; Abstract S5-5.

Gianni L et al. AVEREL, a randomized Phase III trial to evaluate bevacizumab in combination with trastuzumab + docetaxel as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. *Proc SABCS* 2011; Abstract S5-5.


Jones S et al. Phase II trial of adjuvant TC (docetaxel/cyclophosphamide) plus trastuzumab (HER TC) in HER2 positive early stage breast cancer patients. *Proc SABCS* 2011; Abstract PD07-03.


Yardley DA et al. Phase II study evaluating lapatinib in combination with nab®-paclitaxel in women who have received ≤1 chemotherapy regimen for HER2-overexpressing metastatic breast cancer. *Proc SABCS* 2011; Abstract P1-12-10.

Module 2: Multigene/Biomarker Assays

Gonzalez-Angulo AM et al. SWOG S1007: A Phase III, randomized clinical trial of standard adjuvant endocrine therapy +/-chemotherapy in patients with 1-3 positive nodes, hormone receptor (HR)-positive and HER2-negative breast cancer with Recurrence Score (RS) of 25 or less. *Proc SABCS* 2011; Abstract OT1-03-01.

Rezai M et al. Impact of the Recurrence Score on adjuvant decision-making in ER-positive early breast cancer — Results of a large prospective multicentre decision impact study in node negative and node positive disease. *Proc SABCS* 2011; Abstract P2-12-26.


Module 3: Advanced ER-Positive Disease


Module 4: HER2-Negative, BRCA1/2 Mutant Breast Cancer


Miller KD et al. PARP inhibition after preoperative chemotherapy in patients with triple-negative breast cancer (TNBC) or known BRCA1/2 mutations: Hoosier Oncology Group BRE09-146. Proc SABCS 2011;Abstract OT3-01-05.


Module 5: Bone-Targeted Therapy

De Boer R et al. Long-term survival outcomes among postmenopausal women with hormone receptor-positive early breast cancer receiving adjuvant letrozole and zoledronic acid: 5-year follow-up of ZO-FAST. Proc SABCS 2011;Abstract S1-3.


Paterson AHG et al. NSABP protocol B-34: A clinical trial comparing adjuvant clodronate vs placebo in early stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy — Final analysis. Proc SABCS 2011;Abstract S2-3.